cerebrospinal fluid (CSF) . No culture of the organism was performed. There was no 59 evidence of microsporidia in the feces of patient's dog; unfortunately, its urine and 60 serum could not be sampled. The patient was given albendazole 400 mg twice daily 61 for four weeks and 400 mg daily until her CD4 cell count raised up to 100/mm 3 (9 62 months). MMF was switched to azathioprine. This treatment led to clinical 63 improvement, including resolution of fever after 5 days of treatment and reduction of 64 abdominal pain after 2 weeks of treatment. Serum creatinine level decreased to 63 65 µmol/L. However, rare microsporidian spores continued to be shed in urine. 66
Complete clearance of spores was observed only 5 months and a half after treatment 67
initiation. 68
Molecular specific identification. DNA was extracted from the patient's specimens 69 (urines, kidney biopsy, sputum, CSF, stools and duodenal biopsy) by using the 70 QIAamp DNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer's 71 instructions, after an initial 30-min incubation step with 10 U lyticase at 37°C (Sigma 72 Aldrich, Saint Quentin Fallavier, France). Species diagnosis was made by amplifying 73 a 938-bp fragment of E. cuniculi small subunit rRNA gene by using 5'-74 GTGGTCTGCCCCTGTGGGGT-3' and 5'-CCCTCACAGCAGGCAGAAGC-3' primers 75 (13). Amplification was performed on an 9700 PCR system (Applied Biosystems, 76 cuniculi genotype III had been isolated in 2 non-HIV immunocompromised patients 137 (10, 12, 14) . E. cuniculi type I had been detected in the iris tumor biopsy of one 138 patient (6). Our patient was infected with a newly discovered genotype. 139
Identification of the infecting species of microsporidia is determinant for treatment 140 choice. Albendazole has demonstrated activity against E. cuniculi in vitro (2) and E. 141 intestinalis in vivo in patients with AIDS (11). Four out of 6 non-HIV 142 immunocompromised patients with E. cuniculi infection have been treated with 143
albendazole, associated with fumagillin eye drops in 3 patients with ocular infection 144 (Table 1) . Clinical improvement was seen in all treated patients but relapses occurred 145 after treatment interruption in 2 patients: one patient died from cerebral E. cuniculi 146 infection 4 months after treatment (10) and the other one experienced a relapse 1 147 year after (5). In our patient, parasite shedding in urine decreased but did not cease 148 completely until 5 months and a half after the beginning of treatment. 
